Back to News
Market Impact: 0.2
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookCompany FundamentalsProduct Launches
ResMed outlined its growth, margin and portfolio strategy at a Morgan Stanley discussion, emphasizing demand generation, patient adherence and continued innovation in sleep and respiratory care. The update signals a constructive operational outlook but provided no new financial targets, earnings figures or material product details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
MS0.05
RMD0.42
More News
- Chip stocks snap back on multi-billion-dollar AI bet - AI Strategy got in early
- London neocloud Nscale takes its $1B loss to Wall Street
- Morgan Stanley warns of a 7% S&P 500 dip as rebound catalysts emerge
- Paramount Skydance stock in Focus as odds of Warner Bros deal closing rise
- Drug developer ADARx seeks $1.74 billion valuation in US IPO
- Morgan Stanley's top picks list trounced the S&P 500 the last 12 months. Here are the new members